A recent Health Canada safety advisory comes following an updated safety review of breast implants and the associated risk of BIA-ALCL. According to the April 6, 2022 Health Canada advisory "Advisory - Updated safety review of breast implants underscores the continuing importance of monitoring for cancer; increased risk with highly textured … [Read more...]
FDA Sets New Regulations for Breast Implant Manufacturers
An October 2021 article, "FDA sets stronger safety warnings for breast implants", addresses the Food and Drug Administration's (FDA) new requirements for breast implant manufacturers. The new regulations will require patients receive detailed information about the potential risks and complications of implants prior to receiving surgery. However, … [Read more...]
BIA-ALCL Current Recommendations and Potential Future FDA Guidance Changes
History of BIA-ALCL In 2011, the Food and Drug Administration (FDA) reported 34 cases worldwide of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL), bringing this unique disease into the public eye for the first time. Since then, BIA-ALCL has been recognized internationally as a distinct type of cancer, and prompted the 2019 … [Read more...]
BIA-ALCL Case Studies Confirm Importance of Proper Treatment
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare cancer of the immune system. BIA-ALCL has been closely linked with textured surface breast implants. What Causes BIA-ALCL? While BIA-ALCL is rare, it is very serious and potentially fatal if not treated properly. According to this December 2020 article, "Etiology of … [Read more...]
Allergan Aesthetics Launches Tracking Campaign for U.S. Breast Implant Patients
Since the July 2019 voluntary recall of textured breast implant Biocell, pharmaceutical company Allergan has been under fire. The recall came after research linked the implant with cases of breast implant associated anaplastic large cell lymphoma (BIA-ALCL). Allergan plans to launch a tracking campaign for U.S. breast implant patients in the near … [Read more...]
FDA Recalls Allergan Textured Implants
We have consistently provided updates on the situation of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) in relation to textured implants. Every article prior to this one has discussed how other countries have banned textured breast implants or how the FDA has been monitoring the issue. As of July 24, 2019 the FDA has finally … [Read more...]
Breast Implants Lymphoma Cancer Cases Update February 2019 – US & Canada
In February 2019 the FDA announced that it has received a total of 660 medical device reports (MDRs) regarding breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), cases in the United States since 2010. This new total indicates an increase of about 246 new reports of breast implants lymphoma cancer cases in the past year. According … [Read more...]
Several 2018 Breast Implant Lymphoma Cancer Lawsuits Already Filed
Background Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) is a type of non-Hodgkin's lymphoma, which is a cancer of the cells of the immune system. This rare T-cell lymphoma can develop as a result of breast implants, though the mechanism of injury is not fully understood at this time. However, based on current data from the … [Read more...]
FDA Provides Updated Number of Breast Implants Lymphoma Cancers
About BIA-ALCL The U.S. Food and Drug Administration (FDA) has been aware of the possible connection between breast implants and breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) since 2011. This condition is a rare type of non-Hodgkin’s lymphoma, which is a cancer of the immune system, rather than a cancer of the breast … [Read more...]